Actinium Pharmaceuticals
NY - New YorkPharmaceutical
Focus: Actinium Pharmaceuticals is a specialized radiotherapy company focused on targeted cancer treatments, particularly in acute myeloid leukemia. The company operates as a mid-cap biotech with a differentiated modality in the competitive oncology space.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Actinium Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow Actinium Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
LeukemiaClinical Trials (1)
NCT00672165Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies
Phase 1Help build intelligence for Actinium Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.